We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this article, we will summarize the bulls’ thesis on VERV. Verve Therapeutics, Inc.’s share was trading at $11.26 as of June 26th.
A scientist in a laboratory working on a gene editing tool, to create treatments for rare genetic diseases.
Verve Therapeutics’ stock surged an astounding 75% following Eli Lilly’s $1.3 billion acquisition announcement, signaling a pivotal moment for the biotech space. At the heart of this excitement is VERVE-102, Verve’s lead drug candidate targeting cardiovascular disease. The therapy, which aims to eliminate chronic disease management through gene editing, could mark a paradigm shift in how heart disease is treated.
The FDA’s Fast Track designation for VERVE-102 further underscores the drug’s breakthrough potential and validates Verve’s scientific approach. Eli Lilly’s substantial bid is a clear vote of confidence, suggesting the pharma giant sees transformational value in Verve’s pipeline. The acquisition not only provides financial validation but also shines a light on the evolving landscape of biotech, where high-impact innovation meets large-scale pharmaceutical backing. From a technical perspective, bullish momentum remains strong above $11.27, with caution advised if the stock dips below $10.95.
Beyond the numbers, this deal exemplifies how cutting-edge therapies are attracting serious capital and reshaping the future of medicine. The excitement surrounding Verve’s breakthrough technology and Eli Lilly’s aggressive investment underscores the growing belief in gene editing as a frontier in healthcare. For investors, this move by Lilly isn’t just about Verve—it reflects a broader confidence in biotech’s ability to redefine chronic disease care.
With VERVE-102 leading the charge and now bolstered by big pharma support, Verve appears well-positioned at the intersection of innovation and real-world impact, making this a landmark moment for the company and the sector at large.
Previously we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by Two Natural Cap in June 2025, which highlighted the company’s role in a groundbreaking base-editing therapy for a rare liver disorder. The company’s stock price has appreciated approximately by 12.4% since our coverage. The thesis still stands as CRSP advances gene-editing leadership. Stock Region shares a similar outlook but emphasizes Verve’s cardiovascular focus.
VERV isn’t on our list of the 30 Most Popular Stocks Among Hedge Funds. While we acknowledge the risk and potential of VERV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.